PCI Biotech investor relations material
Listen to the latest call from PCI Biotech
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's proprietary PCI technology targets tumors by non-invasively targeting PECAM-1 receptors on tumor blood vessels using light-activated prodrugs. It has been granted patent protection in the United States, European Union, and certain other jurisdictions for certain uses of its technologies and products.